Optimizing Downstream Processing for an Inactivated Rabies Vaccine

contributed by MilliporeSigma | 06/10/2021

Youness Cherradi, PhD, Senior Process Development Scientist, EMEA, Bioprocessing
Youssef Gaabouri, Associate Director Sales, North & West Africa, Bioprocessing
Anissa Boumlic, PhD, Head of Global Vaccine & Plasma Segments, Bioprocessing

Héla Kallel, PhD, Head of the Biotechnology Development Group
Khaled Trabelsi, PhD, Senior Engineer, interim Head of the Biotechnology Development Group

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!

Email*

Choose a password*

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.